ORPHAN DRUG ASSAYS
For a long time, pharma companies have looked to large disease populations as the biggest potential revenue streams. That perception has shifted. Orphan drugs–pharmaceutical treatments for rare diseases or disorders have proven themselves financially viable, and the industry has taken note.
The list of top projected 2018 sellers includes treatments ranging from Roche’s Rituxan, to therapies like Soliris from Alexion and Kalydeco from Vertex, whose makers are trying to expand the small patient populations that keep them afloat. KRISHGEN with their background in assay development can help you in your journey of research for orphan- drugs. We have an existing portfolio of assays for orphan-drugs and are working to increase this. With the goal focus shifting to seeing new efficacies for existing drugs, we are positioned to help you with offering you customized kits to suit your research and application.
For New Product Development, contact us at: email@example.com
Interferon beta-1a (ABVONEX*) ELISAPemetrexed (ALIMTA*) ELISAIpilimumab (YERVOY*) ELISA
*Note: All trademarks and brands are properties of their respective owners.
Showing all 19 results